Autism ETF ASD returns 10.3% and donates advisory profits

The Defiance Autism Impact ETF (ASD) began trading on June 1. Since launch the fund has returned 10.3% and will donate 100% of its net advisory profits for the first two years. The fund charges an expense ratio of 79 basis points.

ASD tracks the VettaFi Autism Impact Index and targets developed-market companies involved in autism research, clinical care, behavioral services and assistive technologies. The index uses an equal-weighted design to distribute weight evenly across constituent firms rather than concentrating on a small number of large holdings.

The fund sponsor has committed to donate at least 50% of net advisory profits after the initial two-year period. Donations are directed to organizations that support autism research, clinical care and improved access to resources for autistic people.

Data since the fund’s launch shows the 10.3% return compared with a 14% average for the health and biotech equities category over the same period; ASD outperformed that category over the most recent month. One of the fund’s largest holdings, Definium Therapeutics (DFTX), was up 209% year-to-date as of the end of July and contributed to the fund’s performance.

VettaFi LLC is the index provider and receives a licensing fee. VettaFi is not the issuer, sponsor or seller of ASD and has no obligations related to the ETF’s issuance, administration, marketing or trading.

The fund offers investors exposure to companies linked to autism-related research and services while incorporating a formal donation commitment into its operating plan.